Lasa Supergenerics financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹1.2cr−93.9% on Q1 FY26
Net profit
−₹3.6cr−₹21.1 cr in Q1 FY26
EBITDA margin
−113.4%−110.9 pts on Q1 FY26
EPS
−₹0.71−₹4.22 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue1.220.0−93.9%
EBITDA−1.4−0.5—
EBITDA margin−113.4%−2.5%−110.9 pts
Profit before tax−3.5−22.5—
Net profit−3.6−21.1—
EPS−₹0.71−₹4.22—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹1.2 crNet profit₹−3.6 crNet margin−291.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
23.4————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.30.30.30.60.8
9.79.72.622.10.0
32.9————
6.425.1142104130
—−82.4%+36.5%−19.5%—
−8.7−28.46.32.2−6.6
−137.2%−113.0%4.4%2.1%−5.1%
−14.7−34.4−6.0−8.5−20.0
−16.5−34.1−14.8−21.7−38.6
−260.4%−135.6%−10.4%−20.8%−29.8%
−₹3.30−₹6.80−₹2.95−₹4.34−₹7.71
—−131.0%+32.1%+43.7%—
—−22.8−2.82.1−33.5
—0.00.0−0.7−4.8
−22.8−22.8−2.81.5−38.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹23.4 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————23.4
- Cash, Equiv & ST Investments0.80.60.30.30.3
+ Total Debt0.022.12.69.79.7
Enterprise Value————32.9
Revenue129.6104.3142.425.16.4
Growth %, YoY—-19.5+36.5-82.4—
EBITDA-6.62.26.3-28.4-8.7
Margin %-5.092.084.40-112.98-137.17
EBIT-20.0-8.5-6.0-34.4-14.7
Net Income-38.6-21.7-14.8-34.1-16.5
Margin %-29.81-20.83-10.36-135.60-260.40
EPS, Adj (current shares)-7.71-4.34-2.95-6.80-3.30
Growth %, YoY—+43.7+32.1-131.0—
Cash from Operations-33.52.1-2.8-22.8—
Capital Expenditures-4.8-0.7-0.0-0.0—
Free Cash Flow-38.31.5-2.8-22.8-22.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Lasa Supergenerics financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Lasa Supergenerics (NSE: LASA) had a market capitalisation of ₹23.4 crore at the previous close (₹4.67 a share) and a price-to-book ratio of 0.47. In FY26 its consolidated net loss was ₹34.1 crore on revenue of ₹25.1 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹3.6 crore. Its debt-to-equity ratio was 0.20 on 31 March 2026. Promoters held 53.65% of the shares on 30 September 2026.

Share price used
₹4.67 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Lasa Supergenerics at a glance · consolidated

Market cap
₹23.4 Crat ₹4.67 · previous close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
0.47book value ₹9.90 a share
ROE (FY26)
−51.1%−34.8 pts vs FY25ROCE −51.4%
Debt to equity
0.20net debt ₹9.1 Cr
Promoter holding
53.65%30 September 2026
Net worth
₹49.6 Cr−40.7% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹22.8 Cr
EPS (FY26)
−₹6.80

Questions

What is the Lasa Supergenerics PE ratio today?

Lasa Supergenerics' PE ratio is not meaningful at the previous close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹16.5 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹23.4 crore at ₹4.67 a share.

What is the Lasa Supergenerics PB ratio (price to book value)?

Lasa Supergenerics' price-to-book (PB) ratio is 0.47 at the previous close: a market capitalisation of ₹23.4 crore divided by shareholders' equity (book value) of ₹49.6 crore on 31 March 2026. That is a book value of ₹9.90 per share against a share price of ₹4.67.

What is the Lasa Supergenerics book value per share?

Lasa Supergenerics' book value per share was ₹9.90 on 31 March 2026: shareholders' equity of ₹49.6 crore divided by the 5.01 crore shares in issue, down 40.7% from ₹16.71 a year earlier. The share price at the previous close was ₹4.67.

What is the Lasa Supergenerics market cap?

Lasa Supergenerics' market capitalisation was ₹23.4 crore at the previous close: 5.01 crore shares at ₹4.67 each.

Is Lasa Supergenerics debt free?

No. Lasa Supergenerics had borrowings of ₹9.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.20. Its cash and current investments were ₹70 lakh, so its net debt was ₹9.1 crore.

What is the Lasa Supergenerics EPS?

Lasa Supergenerics' basic earnings per share (EPS) were −₹6.80 in FY26, against −₹2.95 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹3.30.

What is the Lasa Supergenerics debt to equity ratio?

Lasa Supergenerics' debt-to-equity ratio was 0.20 on 31 March 2026: borrowings of ₹9.7 crore against total equity of ₹49.6 crore. A year earlier, on 31 March 2025, it was 0.03.

What is the Lasa Supergenerics net worth?

Lasa Supergenerics' net worth — shareholders' equity in its consolidated balance sheet — was ₹49.6 crore on 31 March 2026, down 40.7% from ₹83.7 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹23.4 crore at the previous close.

What is the Lasa Supergenerics shareholding pattern?

On 30 September 2026, Lasa Supergenerics' shares were held by promoters 53.65%, foreign portfolio investors (FII/FPI) 0.00% and retail and other non-institutional investors 46.35%.

What is the Lasa Supergenerics ROE and ROCE?

In FY26, Lasa Supergenerics' return on equity (ROE) was −51.1% and its return on capital employed (ROCE) was −51.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −16.4% and ROCE −6.5%.

What are the Lasa Supergenerics latest quarterly results?

Lasa Supergenerics' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net loss ₹3.6 crore, narrower than the loss of ₹21.1 crore in Q1 FY26; revenue from operations ₹1.2 crore, down 93.9% year on year.

Lasa Supergenerics vs Mangalam Drugs And Organics: how do they compare?

In FY26, Lasa Supergenerics earned net profit of ₹34.1 crore on revenue of ₹25.1 crore, against ₹44.4 crore on ₹232 crore for Mangalam Drugs And Organics. Lasa Supergenerics' operating margin was −136.9% (Mangalam Drugs And Organics −14.3%) and its return on equity −51.1% (Mangalam Drugs And Organics −35.2%).

What is the Lasa Supergenerics promoter holding?

Promoters held 53.65% of Lasa Supergenerics on 30 September 2026, unchanged from a year earlier, according to the shareholding pattern filed with NSE.

What is the Lasa Supergenerics free cash flow?

In FY26, Lasa Supergenerics generated ₹22.8 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹22.8 crore. In FY25 it was −₹2.8 crore.

When are the Lasa Supergenerics next results?

Lasa Supergenerics has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Lasa Supergenerics revenue and profit in FY26?

In FY26 (April 2025–March 2026), Lasa Supergenerics' consolidated net loss was ₹34.1 crore, wider than the loss of ₹14.8 crore in FY25, on revenue from operations of ₹25.1 crore (down 82.4%).

How does Lasa Supergenerics compare with its peers?

On FY26 consolidated figures, against Mangalam Drugs And Organics, Biofil Chemicals & Pharmaceuticals and ORTIN GLOBAL: Lasa Supergenerics' operating margin of −136.9% is the third highest of the four (Mangalam Drugs And Organics −14.3%, Biofil Chemicals & Pharmaceuticals 1.3%, ORTIN GLOBAL −1,030.6%; peer average −347.8%); its return on equity of −51.1% is the lowest of the four (Mangalam Drugs And Organics −35.2%, Biofil Chemicals & Pharmaceuticals 13.8%, ORTIN GLOBAL −46.1%; peer average −22.5%).

Where do these Lasa Supergenerics figures come from?

From Lasa Supergenerics' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.